AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12368570 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg olmesartan medoxomil q.d.
Number of subjects: 334
Study 12368570 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg olmesartan medoxomil q.d.
Number of subjects: 334
Study 12368570 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg olmesartan medoxomil q.d.
Number of subjects: 334
Study 12368570 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg olmesartan medoxomil b.i.d.
Number of subjects: 334
Study 12368570 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg olmesartan medoxomil b.i.d.
Number of subjects: 334
Study 12368570 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg olmesartan medoxomil b.i.d.
Number of subjects: 334
Study 12368570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 334
Study 10202830 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate 65 mg weekly
Number of subjects: 30
Study 10202830 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate 195 mg weekly
Number of subjects: 30
Study 10202830 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate 200 mg fortnightly (open-label)
Number of subjects: 30
Study 10202830 — intervention group
Group type: EXPERIMENTAL
Intervention: DEXA, BIS, D2O methods
Number of subjects: 30
Study 10202830 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS method
Number of subjects: 30
Study 10202830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7851572 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial hCG titer < 1,000 mIU/mL
Number of subjects: 67
Study 7851572 — intervention group
Group type: EXPERIMENTAL
Intervention: Trend in hCG titers between first and second sample
Number of subjects: 67
Study 7851572 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic visualization of absence of an ectopic gestational sac
Number of subjects: 67
Study 7851572 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial hCG titer and trend in hCG titers
Number of subjects: 67
Study 1967338 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver transplantation
Number of subjects: 0
Study 1967338 — intervention group
Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 0
Study 1967338 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency hepatic transplantation
Number of subjects: 0
Study 335419 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam (3 tablets or 1.2 g for second and third graders; 5 tablets or 2.0 g for fourth graders)
Number of subjects: 66
Study 335419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 30535534 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum, Lactobacillus fermentum, 2 × 10^9 CFU/g each) for 6 weeks
Number of subjects: 48
Study 30535534 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 48
Study 27511906 — intervention group
Group type: EXPERIMENTAL
Intervention: Active acupuncture (AA)
Number of subjects: 42
Study 27511906 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (SA)
Number of subjects: 42
Study 24447266 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine (6 ml.h(‐1))
Number of subjects: 60
Study 24447266 — intervention group
Group type: COMPARATOR
Intervention: 0.5% ropivacaine (6 ml.h(‐1))
Number of subjects: 60
Study 23739196 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulimorelin 160 µg/kg
Number of subjects: 662
Study 23739196 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulimorelin 480 µg/kg
Number of subjects: 662
Study 23739196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 662
Study 20545209 — intervention group
Group type: EXPERIMENTAL
Intervention: Fupiyiwei decoction (FPYWD) combined with chemotherapy
Number of subjects: 58
Study 20545209 — intervention group
Group type: COMPARATOR
Intervention: Control group (chemotherapy only)
Number of subjects: 58
Study 17368874 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured medium and long chain triglycerides (StO)
Number of subjects: 23
Study 17368874 — intervention group
Group type: COMPARATOR
Intervention: Extra virgin olive oil (OO)
Number of subjects: 23
Study 17368874 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets (StO and OO)
Number of subjects: 23
Study 15935270 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct restorations
Number of subjects: 11
Study 15935270 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-direct restorations
Number of subjects: 11
Study 12841885 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg/day) continuously
Number of subjects: 212
Study 12841885 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogen (0.625 mg/day) and medroxyprogesterone acetate (5 mg/day) continuously
Number of subjects: 212
Study 12841885 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (0.625 mg/day) continuously (hysterectomized women)
Number of subjects: 212
Study 12841885 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen (50 microg/day) and medroxyprogesterone acetate (5 mg/day) continuously
Number of subjects: 212
Study 12841885 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen (50 microg/day) continuously (hysterectomized women)
Number of subjects: 212
Study 12841885 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 212
Study 11299497 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 g i.v. amoxicillin/clavulanic acid (Group 1)
Number of subjects: 435
Study 11299497 — intervention group
Group type: COMPARATOR
Intervention: Other antibiotics commonly used for prophylaxis (Group 2)
Number of subjects: 435
Study 11299497 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic prophylaxis (Group 3)
Number of subjects: 435
Study 1996000 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose of epinephrine (1 mg)
Number of subjects: 32
Study 1996000 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of epinephrine (0.2 mg/kg)
Number of subjects: 32
Study 6350014 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant leukocyte alpha 2 interferon (rIFN) at various dosages (0.3 X 10(6) IU, 1 X 10(6) IU, 3 X 10(6) IU, 10 X 10(6) IU, 30 X 10(6) IU, 100 X 10(6) IU)
Number of subjects: 27
Study 6350014 — intervention group
Group type: COMPARATOR
Intervention: Low dose (0.01 X 10(6) IU)
Number of subjects: 27
Study 30690609 — intervention group
Group type: EXPERIMENTAL
Intervention: TheraBracelet stimulation during task-practice therapy
Number of subjects: 12
Study 30690609 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (control group)
Number of subjects: 12
Study 30429694 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen
Number of subjects: 57
Study 30429694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 26735516 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed dye laser (PDL)
Number of subjects: 20
Study 26735516 — intervention group
Group type: COMPARATOR
Intervention: Long-pulsed Nd:YAG laser
Number of subjects: 20
Study 24499959 — intervention group
Group type: EXPERIMENTAL
Intervention: Group T1 (T1/Tc ratio of 50%)
Number of subjects: 61
Study 24499959 — intervention group
Group type: COMPARATOR
Intervention: Group TOF (maintenance of two train‐of‐four counts)
Number of subjects: 61
Study 22311445 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole + Amoxicillin + Clarithromycin (OAC group)
Number of subjects: 85
Study 22311445 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole (OAM group)
Number of subjects: 85
Study 20023578 — intervention group
Group type: EXPERIMENTAL
Intervention: Intellectual disability group (ID)
Number of subjects: 77
Study 20023578 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 77
Study 20023578 — intervention group
Group type: EXPERIMENTAL
Intervention: Syndromic etiology among individuals with ID
Number of subjects: 77
Study 17947836 — intervention group
Group type: EXPERIMENTAL
Intervention: Telecare (glucometer transmission with feedback, group A)
Number of subjects: 28
Study 17947836 — intervention group
Group type: COMPARATOR
Intervention: Control (standard communication by phone and face-to-face visits, group B)
Number of subjects: 28
Study 16290959 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen alone
Number of subjects: 232
Study 16290959 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus medroxyprogesterone acetate
Number of subjects: 232
Study 16290959 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen and estrogen plus medroxyprogesterone
Number of subjects: 232
Study 16290959 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen (active treatment arm)
Number of subjects: 232
Study 11981142 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Number of subjects: 44
Study 11981142 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 44
Study 11981142 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam (active placebo)
Number of subjects: 44
Study 11981142 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (dose-response)
Number of subjects: 44
Study 10772554 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg (two doses)
Number of subjects: 103
Study 10772554 — intervention group
Group type: COMPARATOR
Intervention: Control (uninfected children at baseline)
Number of subjects: 103
Study 10772554 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in Trichuris intensity
Number of subjects: 103
Study 10772554 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in Ascaris intensity
Number of subjects: 103
Study 7554327 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Number of subjects: 11
Study 1766725 — intervention group
Group type: EXPERIMENTAL
Intervention: OPV‐OPV‐OPV (Group A)
Number of subjects: 123
Study 1766725 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV‐IPV‐IPV (Group B)
Number of subjects: 123
Study 1766725 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV‐OPV‐OPV (Group C)
Number of subjects: 123
Study 1766725 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV‐IPV‐OPV (Group D)
Number of subjects: 123
Study 7250471 — intervention group
Group type: EXPERIMENTAL
Intervention: Salicylic acid
Number of subjects: 0
Study 7250471 — intervention group
Group type: COMPARATOR
Intervention: Water/oil emulsion
Number of subjects: 0
Study 7250471 — intervention group
Group type: COMPARATOR
Intervention: Urea
Number of subjects: 0
Study 31794624 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Section 8 voucher
Number of subjects: 4604
Study 31794624 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-poverty voucher
Number of subjects: 4604
Study 31794624 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4604
Study 28810024 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (n=64) including 5 to 6 weekly aerobic training sessions (30-60 minutes) and dietary plans aiming for a BMI of 25 or less.
Number of subjects: 98
Study 28810024 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n=34) with individual counseling and standardized medical therapy.
Number of subjects: 98
Study 28810024 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (n=64)
Number of subjects: 98
Study 28810024 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n=34)
Number of subjects: 98
Study 26905272 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS + CIMT
Number of subjects: 14
Study 26905272 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS + CIMT
Number of subjects: 14
Study 26905272 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS + CIMT and Sham rTMS + CIMT
Number of subjects: 14
Study 25090043 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based community reinforcement approach intervention plus contingency management (CRA+) and buprenorphine
Number of subjects: 170
Study 25090043 — intervention group
Group type: COMPARATOR
Intervention: Contingency management alone (CM-alone) plus buprenorphine
Number of subjects: 170
Study 22292521 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized treatment based on early treatment response
Number of subjects: 192
Study 22292521 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment based on early treatment response
Number of subjects: 192
Study 19053020 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild increased physical activity (walking about 800 meters/day)
Number of subjects: 8
Study 19053020 — intervention group
Group type: COMPARATOR
Intervention: Habitual activity
Number of subjects: 8
Study 17805102 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (60 mg.d(‐1) for 1 wk)
Number of subjects: 10
Study 15196525 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle arthrodesis fused in a neutral position
Number of subjects: 19
Study 15196525 — intervention group
Group type: COMPARATOR
Intervention: Control group (walking barefoot)
Number of subjects: 19
Study 12380850 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized trials
Number of subjects: 324
Study 12380850 — intervention group
Group type: COMPARATOR
Intervention: Nonrandomized trials
Number of subjects: 324
Study 9810581 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar resurfacing (Group A)
Number of subjects: 40
Study 9810581 — intervention group
Group type: COMPARATOR
Intervention: No patellar resurfacing (Group B)
Number of subjects: 40
Study 8129501 — intervention group
Group type: EXPERIMENTAL
Intervention: CME (Continuing Medical Education)
Number of subjects: 3158
Study 8129501 — intervention group
Group type: EXPERIMENTAL
Intervention: CME+QA (Continuing Medical Education with Quality Assurance)
Number of subjects: 3158
Study 8129501 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 3158
Study 8129501 — intervention group
Group type: EXPERIMENTAL
Intervention: CME vs Control
Number of subjects: 3158
Study 8129501 — intervention group
Group type: EXPERIMENTAL
Intervention: CME+QA vs CME
Number of subjects: 3158
Study 2187928 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 34
Study 2187928 — intervention group
Group type: COMPARATOR
Intervention: Netilmicin and azlocillin
Number of subjects: 34
Study 6107725 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg DAMME (FK33-824, Sandoz) infusion
Number of subjects: 0
Study 6107725 — intervention group
Group type: COMPARATOR
Intervention: Water-deprived volunteers (after DAMME administration)
Number of subjects: 0
Study 6107725 — intervention group
Group type: COMPARATOR
Intervention: Hydrated subjects
Number of subjects: 0
Study 31006694 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task training using various cognitive tasks
Number of subjects: 30
Study 31006694 — intervention group
Group type: COMPARATOR
Intervention: Conventional occupational therapy
Number of subjects: 30
Study 27714763 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiselimod (1 mg·kg‐1)
Number of subjects: 0
Study 27714763 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiselimod
Number of subjects: 0
Study 27714763 — intervention group
Group type: COMPARATOR
Intervention: Fingolimod (1 mg·kg‐1)
Number of subjects: 0
Study 25881262 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily provision of free fruit and vegetables (FV)
Number of subjects: 1121
Study 25881262 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotion of a pleasant eating environment
Number of subjects: 1121
Study 25881262 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily offering of FV by teachers
Number of subjects: 1121
Study 25881262 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutting up FV by teachers
Number of subjects: 1121
Study 25881262 — intervention group
Group type: EXPERIMENTAL
Intervention: High implementation of educational components
Number of subjects: 1121
Study 23666608 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 50 or 100 mg every 4 weeks
Number of subjects: 405
Study 23666608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 405
Study 23666608 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab
Number of subjects: 405
Study 22072405 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine Cognitive Behavioral Therapy (TV‐CBT)
Number of subjects: 116
Study 22072405 — intervention group
Group type: COMPARATOR
Intervention: Face-to-Face Cognitive Behavioral Therapy (FTF‐CBT)
Number of subjects: 116
Study 19131420 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 166
Study 19131420 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertion of tympanostomy tubes with adenoidectomy
Number of subjects: 166
Study 19131420 — intervention group
Group type: COMPARATOR
Intervention: Insertion of tympanostomy tubes without adenoidectomy
Number of subjects: 166
Study 17471295 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral and pharmacological treatment
Number of subjects: 180
Study 15071400 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 10
Study 15071400 — intervention group
Group type: COMPARATOR
Intervention: Dopamine
Number of subjects: 10
Study 11333047 — intervention group
Group type: EXPERIMENTAL
Intervention: Overdrive pacing at 60 bpm
Number of subjects: 18
Study 11333047 — intervention group
Group type: EXPERIMENTAL
Intervention: Overdrive pacing at 75 bpm
Number of subjects: 18
Study 11333047 — intervention group
Group type: EXPERIMENTAL
Intervention: Overdrive pacing at 90 bpm
Number of subjects: 18
Study 11333047 — intervention group
Group type: COMPARATOR
Intervention: Standard lower rate limit of 60 bpm
Number of subjects: 18
Study 9725752 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 9725752 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 0
Study 8039612 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphapheresis (9 procedures within 4-5 weeks)
Number of subjects: 28
Study 8039612 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 28
Study 8039612 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphapheresis
Number of subjects: 28
Study 8039612 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study 2568520 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-heparin, 12,500 U, subcutaneously
Number of subjects: 711
Study 5342 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg
Number of subjects: 6
Study 5342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30995905 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (INT)
Number of subjects: 1550
Study 28556806 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle (PFM) exercises with simultaneous tension of the transverse abdominal muscle (TrA) for 3 months, 4 weekly sessions
Number of subjects: 140
Study 28556806 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor muscle (PFM) exercises without TrA tension for 3 months, 4 weekly sessions
Number of subjects: 140
Study 24977700 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6.04 +/- 0.16 mg/kg)
Number of subjects: 30
Study 24977700 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 30
Study 24977700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 23597658 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention emphasizing 'Stand Up, Sit Less, Move More'
Number of subjects: 43
Study 21240873 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus + CsA + steroids
Number of subjects: 106
Study 21240873 — intervention group
Group type: COMPARATOR
Intervention: EC‐MPS + CsA + steroids
Number of subjects: 106
Study 19295192 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with n‐3 long‐chain polyunsaturated fatty acids (FAs)
Number of subjects: 204
Study 19295192 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric control diet
Number of subjects: 204
Study 16597671 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic transformation applied to bounded outcome scores
Number of subjects: 0
Study 16597671 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic transformation with equal variances
Number of subjects: 0
Study 16597671 — intervention group
Group type: EXPERIMENTAL
Intervention: Ignoring inequality of variances
Number of subjects: 0
Study 16597671 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation study comparing performance
Number of subjects: 0
Study 16597671 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of methods on two data sets
Number of subjects: 0
Study 15217964 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib (Iressa) as second-line therapy
Number of subjects: 1000
Study 15217964 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib in combination with chemotherapy (first-line therapy)
Number of subjects: 1000
Study 15217964 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib (not specified)
Number of subjects: 1000
Study 11704778 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 75 mg
Number of subjects: 1620
Study 11704778 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 25 mg
Number of subjects: 1620
Study 11704778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1620
Study 11704778 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 75 mg and 25 mg
Number of subjects: 1620
Study 11704778 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 1620
Study 9152715 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline (10 mg)
Number of subjects: 25
Study 9152715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 7535550 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal therapy
Number of subjects: 32
Study 3321153 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextro-propranolol
Number of subjects: 36
Study 3321153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 31584721 — intervention group
Group type: EXPERIMENTAL
Intervention: Marriage Checkup (two‐session Assessment and Feedback relationship intervention)
Number of subjects: 209